Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report
复制标题

DOI:
10.1590/1516-4446-2014-1496
复制
发表时间:
2015-03-01
影响因子:
--
通讯作者:
Hallak, Jaime E.
Hallak, Jaime E.
中科院分区:
医学3区
文献类型:
--
作者:
Osório, Flávia de L.;Sanches, Rafael F.;Hallak, Jaime E.

文献摘要

被引文献

相似文献

目的:Ayahuasca(AYA)是一种天然的迷幻剂,由亚马逊植物制成,富含二甲基色胺(DMT)和骆驼蓬碱,会引起主观幸福感的影响,因此可能具有抗抑郁作用。本研究旨在评估的影响,单剂量的AYA在6名志愿者与当前的抑郁epission.Methods:开放标签试验进行了住院精神科病房。根据汉密尔顿抑郁评定量表(HAM-D)的测量结果,在基线和AYA给药后1、7和21天之间,观察到抑郁评分统计学显著降低高达82%,Montgomery-Asberg抑郁评定量表(MADRS)和简明精神病评定量表(BPRS)的抑郁子量表。AYA给药导致Young Mania Rating Scale(YMRS)评分和BPRS的思维障碍子量表无显著变化,表明AYA不会诱导心境障碍患者的躁狂和/或轻躁狂发作,并且可能表明迷幻效应的思维内容修改对心境改善并不重要。这些结果表明,AYA对抑郁症患者具有快速起效的抗焦虑和抗抑郁作用。
Objectives: Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions. This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode.Methods: Open-label trial conducted in an inpatient psychiatric unit.Results: Statistically significant reductions of up to 82% in depressive scores were observed between baseline and 1, 7, and 21 days after AYA administration, as measured on the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Anxious-Depression subscale of the Brief Psychiatric Rating Scale (BPRS). AYA administration resulted in nonsignificant changes in Young Mania Rating Scale (YMRS) scores and in the thinking disorder subscale of the BPRS, suggesting that AYA does not induce episodes of mania and/or hypomania in patients with mood disorders and that modifications in thought content, which could indicate psychedelic effects, are not essential for mood improvement.Conclusions: These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder.